

[317] BIORETINA

Yaakov Milstain¹, ¹ Nano Retina

- **Investment Rational**

Nano Retina is the only company in the world that develop functional level artificial retina. This implantable device will restore vision to millions of blind patients that no other solution is available for them. The addressable market is higher than \$1 Billion
- **Business Strategy**

Nano Retina's will dominate the market after introduction based on the following competitive advantages:

 - Highest resolution on the market: 600 pixels.
 - Allows free use of eye natural mechanisms including muscle movement and lens focusing.
 - The only minimally invasive implantation procedure: shorter than 1 hour with local anesthesia.
- **Core Technology**

A joint venture of Rainbow Medical and Zyvex Labs, Nano Retina builds on an infrastructure of medical innovation on the one hand, and Micro Electro Mechanical System (MEMS) and Nano-Technology engineering on the other hand, combining all the necessary knowhow and expertise to deliver its product to the market via the shortest possible development and regulatory path.
- **Product Profile/Pipeline**

In first phase Nano Retina developed a prototype validating the miniaturization technologies needed to produce the Bio-Retina. This prototype met all specifications performances during in-vitro and in-vivo testing. In the current phase the fully functional implant was manufactured and is in preclinical safety study. The company plans to conduct preclinical and clinical trials during 2018.
- **What's Next?**

Following clinical trials, Nano Retina intends to pursue an accelerated route to market, firstly in Europe and in the USA afterward